Transforaminal Epidural Injection Within 3 Months; Better Outcome in the Postherpetic Neuralgia

Sangwon Kwak, Francis Sahngun Nahm*, Eun Joo Choi*,Pyung Bok Lee*
Department of Anesthesiology & Pain Medicine, Sheikh Khalifa Specialty Hospital, Ras Al Khaimah, UAE
*Department of Anesthesiology & Pain Medicine, Seoul National University Bundang Hospital, Korea

Introduction

- Postherpetic neuralgia (PHN)
- Post herpetic neuralgia (PHN) is a chronic neuropathic pain condition following herpes zoster infection.
- The cause of HZ has been known to be reactivated varicella zoster virus in the dorsal root ganglion (DRG) or trigeminal ganglion.
- Transforaminal steroid injection (TFSI)
- TFSI allows the direct delivery of a drug to the target nerve in close proximity of the DRG.
- Although many physicians perform TFSIs for the treatment of PHN, it is not known which factors of the patients are associated with the outcome.
- The study purpose
- The purpose of this study was to identify which clinical factors of TFSI are related to the outcome in the treatment of PHN.

Materials and Methods (1)

- Study design: Retrospective cohort study
- Patients
- Patients who were affected by PHN at thoracic and lumbar dermatomes
- Patients who received TFSIs from January 2012 to June 2014 at the pain center of Seoul National University Bundang Hospital, Korea.
- Patients were classified into two groups; "effective (E) group" and "non-effective (N) group" based on the results at 3 months follow up after TFSIs.
- E group: ≥ 50 % reduction from the average daily pain intensity
- N group: < 50 % reduction from average daily pain intensity

Materials and Methods (2)

- Data collections
- Patient's: age, gender, symptom duration before the 1st TFSI, affected dermatome, initial pain intensity, additional TFSI requirement
- History of diabetes mellitus, cancer
- Statistical Analysis
- Student t-test for continuous variables
- Chi-square test for categorical variables
- Binary logistic regression analysis
- Receiver operating characteristic (ROC) curve analysis to determine the cutoff value of symptom duration as a predictor of TFSI effectiveness.

Results

Patients' demographics (total 202 patients)

	N group (n = 85)	E group (n =117)	P value
Sex (M/F)	40/45	50/67	0.542
Age (years, mean ± SD)	68.3 ± 9.5	67.3 ± 10.9	0.496
Symptom Duration (weeks)	21.1 ± 17.9	11.5 ± 14.9	< 0.001
Region (Thoracic/Lumbar, n)	75/10	105/12	0.734
Initial pain score (NRS)	6.3 ± 2.0	6.3 ± 1.6	0.952
Additional TFSI (Y/N)	17/68	23/94	0.952
History of diabetes (Y/N)	21/64	27/90	0.788
History of cancer (Y/N)	6/79	6/111	0.567

Results

Odds ratio (OR) and 95% confidence intervals (CI)

Odus ratio (OK) ai	id 3370 CO	illidelice liite	i vais (Ci)
Variables	P values	OR	95% CI
Sex			
Male		Reference	
Female	0.632	0.856	0.454-1.615
Age			
> 60 years		Reference	
≤ 60 years	0.339	0.705	0.344-1.443
Symptom Duration			
> 12 weeks		Reference	
≤ 12 weeks	< 0.001	0.148	0.077-0.286
Initial pain score (NRS)			
> 4		Reference	
≤ 4	0.489	1.136	0.588-3.035
Additory			
No		Reference	
Yes	0.649	0.833	0.378-1.832
History of diabetes			
No		Reference	
Yes	0.944	1.027	0.494-2.135
History of cancer			
No		Reference	
Yes	0.326	1.883	0.532-6.662

- ROC curve analysis
- Best cut off point: Symptom duration of ≤ 12 weeks
- Sensitivity 84.6%, specificity 56.6%, area under the curve 0.716

Conclusions

 TFSIs seem to be helpful in the PHN patients when performed within 12 weeks.